{"cdcTestId":"2018-0001","testcaseName":"Zoster: Patient has received dose 1 of the RZV (Shingrix) series","vaccineGroup":"ZOSTER","evaluationTestType":"All Valid: Forecast Test","forecastTestType":"Recommended based on interval","assessmentDate":"2022-10-19T00:00:00","patient":{"dob":"1972-10-19T00:00:00","gender":"F"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"zoster recombinant","cvx":"187","mvx":"","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"2","earliestDate":"2022-11-16T00:00:00","recommendedDate":"2022-12-14T00:00:00","pastDueDate":"2023-06-15T00:00:00"},"doses":[{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"zoster recombinant","cvx":"187","mvx":"","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2018-03-27T20:00:00","dateUpdated":"2022-09-27T08:44:47.749","generalDescription":"This test case describes when a patient is administered dose #1 of the RZV vaccine, that a second dose should be forecast.","changedInVersion":"4.27","reasonForChange":"v 4.27 Updated Forecast minimum interval from 8 weeks to 4 weeks, to align with ACIP recommendations."}